No Data
No Data
Insufficient Growth At Kexing Biopharm Co., Ltd. (SHSE:688136) Hampers Share Price
Half-year report for the year 2024.
Summary of Half-Year Report in 2024.
Kexing Biopharm (688136.SH): net income of 11.8773 million yuan in the first half of the year, turning losses into profits year-on-year.
Kexing Biopharm (688136.SH) released its 2024 interim report on August 19th, with operating revenue of 760 million yuan, a year-on-year growth of 17.09%; a net income attributable to shareholders of the listed company of 11.8773 million yuan, a turnaround from loss to profit year-on-year; a net income attributable to shareholders of the listed company after deducting non-recurring gains and losses of 21.5303 million yuan; and a basic earnings per share of 0.06 yuan. The company turned loss into profit during this reporting period, and the net profit attributable to shareholders of the listed company achieved significant growth compared with the same period of the previous year, mainly due to: (1) the sales of Ipilimumab, Sarilumab, and Batectin, the company's core products in this period.
Albumine-gebonden Paclitaxel Van Kexing Biopharm Goedgekeurd Voor EU-markt
Le Paclitaxel Lié À L'albumine De Kexing Biopharm Obtient Une Autorisation De Mise Sur Le Marché De L'UE
No Data
No Data